News & Updates

A quality improvement (QI) intervention is associated with reduced medication administration times for biologic therapy by fast-tracking provider-dependent steps and with fewer emergency room (ER) visits, reveals a recent study.

First-line treatment with pembrolizumab + chemotherapy maintains overall survival (OS) and progression-free survival (PFS) in patients with advanced or metastatic oesophageal cancer, according to an additional 12-month follow-up of the KEYNOTE-590* study presented at ASCO GI 2022.

Endovascular therapy (EVT) in addition to medical therapy appeared to improve outcomes in patients with acute large vessel occlusion (LVO) with large ischaemic core following a stroke, according to results of the RESCUE-Japan LIMIT* trial.

The incidence of engraftment syndrome (ES), a common complication of autologous haematopoietic cell transplantation (HCT), is comparable between melphalan formulations among patients with multiple myeloma and immunoglobulin light chain amyloidosis, reveals a study.

The addition of obinutuzumab, a humanized type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, to a background of standard-of-care (SoC) therapy led to improved renal responses in patients with proliferative lupus nephritis (LN) compared with SoC alone, findings from the phase II NOBILITY trial have shown.

First-line treatment with a combination of nivolumab plus ipilimumab (NIVO + IPI) continues to show long-term survival benefits over sunitinib out to 5 years in patients with advanced clear-cell renal carcinoma (RCC) with sarcomatoid features, according to the CheckMate 214 study presented at GUCS 2022.